CTLA4 and familial pancreatic carcinoma: Despite the dismal activity of single-agent checkpoint blockade in pancreatic cancer, PD-1, PD-L1, and CTLA-4 inhibitors have shown broad antitumor activity as single agents in other tumor types and a relatively tolerable toxicity profile rendering them attractive agents to combine with systemic therapy.